INVESTIGATION OF IN VITRO ACTIVITIES OF 131I/99mTc LABELED PLGA ENCAPCULATED MOLECULES ON VARIOUS CELL LINES
Project no. 119 · Status: Kapanmış · 2017
Summary
Nowadays, it is known that breast, cervical and ovarian cancers are common gynecological cancers in women, and it is seen that especially these cancer types are very popular for drug diagnosis systems. There are many studies in the literature showing that polymer-based nanoparticles such as biocompatible and non-toxic Poly (lactic-co-glycolic acid) (PLGA) are effective in transporting various molecules (plant-derived compounds, chemotherapeutic agents) to targeted cancer cells. In the present study, it is aimed to develop radionuclide labeled drug delivery systems that can offer both diagnosis and treatment opportunities for breast, cervix and ovarian cancers. For this purpose, Curcumin (CUR) obtained from plant roots and Lapatinib (LPT), a chemotherapeutic agent, were encapsulated with PLGA. The synthesized encapsulated molecules (CUR-PLGA and LPT-PLGA) were radiolabeled with Iodine-131 (131I) and Technetium-99m (99mTc) and bioaffinity of radiolabeled compounds (131I-CUR-PLGA and 99mTc-LPT-PLGA) were evaluated on breast, cervix and ovarian cancers by using in vitro methods. In experimental studies, radiolabeling efficiencies of 131I-CUR-PLGA and 99mTc-LPT-PLGA compounds were determined as 98.26 ± 2.08 (n = 4) and 97.68 ± 0.93 (n = 4), respectively. Within the scope of in vitro studies, cytotoxicity and incorporation studies were carried out on the MDA-MB-231, HeLa and MDAH-2774 cell lines. IC50 values of the inactive substances (CUR and LPT) applied as a result of cytotoxicity studies performed were calculated. It is thought that the data obtained in current project will contribute to the development of new agents for radiolabeled polymeric drug delivery systems.